Lucosky Brookman LLP takes Akers Biosciences, Inc. Public on NASDAQ
Initial Public Offering of Common Stock on the NASDAQ Capital Markets, Dual-Listing on the AIM London Stock Exchange, and Capital Raise of $15,000,000;
Lucosky Brookman will join Akers Biosciences to Ring the NASDAQ Closing Bell on July 9, 2014
WOODBRIDGE, N.J., April 3, 2014 /PRNewswire/ -- Lucosky Brookman LLP (the "Firm" or "Lucosky Brookman") (www.lucbro.com), a leading corporate finance and securities law firm, has announced that its client Akers Biosciences, Inc. (the "Company" or "Akers Biosciences") (NASDAQ: AKER) has successfully completed an initial public offering of its common stock and commenced trading on the NASDAQ Capital Markets. Lucosky Brookman will join Akers Biosciences to ring the closing bell on the floor of the NASDAQ on July 9, 2014.
On January 23, 2014, the Firm completed the Company's underwritten public offering in which the Company was successful in raising approximately $15,000,000. The capital raise consisted of an initial public offering of 2,727,000 shares of the Company's common stock at a public offering price of $5.50 per share. The shares began trading on the NASDAQ Capital Market on January 23, 2014 at approximately 2:10 PM EST under the symbol "AKER." The shares will continue to be dual-listed on the AIM London Stock Exchange.
Joseph Lucosky, the Managing Partner of the Firm, commented on the transaction, "Lucosky Brookman was pleased to act as counsel to Akers Biosciences as it makes its first entry into the US capital markets. As with all initial public offerings, our success was due largely to the Firm's effective partnership with Company management and the underwriters. We congratulate the Company on this momentous occasion in the Company's history, as well as Aegis Capital Corp., for their effective assistance as the sole book-running manager for the offering."
Ray Akers Jr., PhD, Executive Chairman of the Board of Directors, remarked "We are overwhelmingly pleased with the outcome of the initial public offering and listing on the NASDAQ. Through Lucosky Brookman's leadership, we were able to successfully raise $15,000,000 and enter the US capital markets. This is a day of tremendous personal accomplishment for me and my family and I know that it would not have been possible without Lucosky Brookman."
ABOUT LUCOSKY BROOKMAN LLP
Lucosky Brookman LLP is a corporate finance and securities law firm with offices in New York, New Jersey and California, representing public companies as well as institutional and privately-held clients, both domestic and internationally, in sophisticated corporate and securities transactions, mergers and acquisitions, secured and unsecured lending transactions, PIPEs and general corporate matters. Additional information on the Firm and its practice areas can be found at www.lucbro.com.
ABOUT AKERS BIOSCIENCES, INC.
Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. Additional information on the Company and its products can be found at www.akersbiosciences.com.
This press release may be considered advertising under the rules of some states. Prior results cannot and do not guarantee or predict a similar outcome.
SOURCE Lucosky Brookman LLP